Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 3055-3060

  Bitossi, Raffaella ^a   Sculli, Carla Maria ^a   Tampellini, Marco ^a,b   Alabiso, Irene ^a   Brizzi, Maria P ^a   Ferrero, Anna ^a   Ottone, Azzurra ^a   Bellini, Elisa ^a   Gorzegno, Gabriella ^a   Berruti, Alfredo ^a   Dogliotti, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

5 Fluorouracil; Colorectal cancer; Gemcitabine; Metastatic disease

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PALLIATIVE THERAPY; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 55749105396     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gill S, Thomas RR and Goldberg RM: Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther 18(7): 683-692, 2003.
2. Midgley R and Kerr D: Colorectal cancer. Lancet 353(9150): 391-399, 1999.
3. Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10(4): 250-261, 2005.
4. Chong G, Dickson JLB, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Gates J and Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93(5): 510-514, 2005.
5. Lim do H, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK and Park K: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56(1): 10-14, 2005.
6. Rosati G, Rossi A, Germano D, Reggiardo G and Manzione L: Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23(3C): 2981-2985, 2003.
7. Gubanski M, Naucler G, Almerud A, Lideståhl A and Lind PA: Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 44(3): 236-239, 2005.
8. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L and Tonini G: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94(6): 792-797, 2006.
9. Rao S, Cunningham D, De Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC and Palmer PA: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22(19): 3950-3957, 2004.
10. Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S and Viola M: Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol 18(20): 3553-3557, 2000.
11. Plunkett W, Huang P, Searcy CE and Gandhi V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(5 Suppl 10): 3-15, 1996.
12. Schultz L, Schalhorn A, Wilmanns W and Heinemann V: Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Proc. ASCO 17: 965 abstr, 1998.
13. Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL and Zoli W: In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 8(1): 233-239, 2002.
14. Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM and Wilding G: A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs 16(4): 325-330, 1998-1999.
15. Kliche KO, Kubsch K, Raida M, Masri-Zada R and Hoffken K: Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients. J Cancer Res Clin Oncol 128(9): 516-524, 2002.
16. Correale P, Cerretani D, Clerici M, Messinese S, Marsili S, Petrioli R, Cetta F, Savelli V, Guarnieri A, Pinto E, Giorgi G and Francini G: Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies. J Chemother 16(2): 206-210, 2004.
17. Correale P, Messinese S, Canaglia M, Marsili S, Piccolomini A, Petrioli R, Ceciarini F, Micheli L, Nencini C, Neri A, Vuolo G, Guarnieri A, Abbruzzese A, Prete SD, Giorgi G and Francini G: A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer 90: 1710-1717, 2004.
18. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E and Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologie and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23(35): 8950-8958, 2005.
19. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR and Moore MJ: Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 15(5): 770-774, 2004.
20. van Riel JM, van Groeningen CJ, Pinedo HM and Giaccone G: Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol 10(Suppl 4): 157-161, 1999.
21. Cascinu S, Frontini L, Labianca R, Catalano V, Barni S, Graiff C, Picone G, Farinati F, Zonato S, Pessi MA, Curti C and Catalano G: A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 11(10): 1309-1311, 2000.
22. Therasse P, Arbruck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-216, 2000.
23. Rothenberg ML, Moore MJ, Cripps MC Andersen JS, Portenoy RK, Burriss HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM and Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7(4): 347-353, 1996.
24. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1): 1-10, 1989.
25. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2): 229-237, 2004.
26. Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7): 1209-1214, 2004.
27. Chua YJ and Zalcberg JR: Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther 8(4): 595-604, 2008.
28. Taieb J, Puig PL and Bedenne L: Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Rev Anticancer Ther 8(2): 183-189, 2008.
29. Labianca R, Milesi L, Mosconi S, Pessi MA, Beretta GD and Quadri A: The role of adjuvant chemotherapy in colon cancer. Surg Oncol 16(Suppl 1): S93-96, 2007.
30. Benson AB 3rd: New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 13(22 Pt 2): 6913s-6920s, 2007.
31. Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, Garcia-Foncillas J and Gil-Bazo I: Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 13(44): 5867-5876, 2007.
32. Lee JJ and Chu E: An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 13(5): 276-281, 2007.